News

Rhythm Pharmaceuticals Advances Setmelanotide for Rare Obesity

Rhythm Pharmaceuticals Advances Setmelanotide for Rare Obesity

Rhythm Pharmaceuticals Makes Strides with Setmelanotide

Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), a company dedicated to transforming the lives of patients living with rare neuroendocrine diseases, has received significant news that impacts its pipeline treatment. The U.S. Food and Drug Administration (FDA) has accepted for filing the company's supplemental New Drug Application (sNDA) for setmelanotide, aimed at treating conditions associated with acquired hypothalamic obesity. The FDA has also granted a Priority Review for this application, highlighting the treatment's potential urgency and importance in addressing unique patient needs.

Priority Review and PDUFA Date

The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of December 20, 2025. This reflects the agency's recognition of the clinical needs that setmelanotide addresses and the seriousness of the condition it aims to treat. The acceptance of the sNDA sets the stage for possible market entry of this vital treatment, which is designed for patients coping with the challenges posed by acquired hypothalamic obesity.

EMA Validation and Ongoing Reviews

In parallel, Rhythm Pharmaceuticals announced validation from the European Medicines Agency (EMA) regarding its Type II variation submission to the Marketing Authorization Application (MAA) for setmelanotide. The significance of this validation cannot be understated, as it not only confirms the application’s adequacy for review but also signifies the potential for broader access to this treatment across Europe.

Significance of Setmelanotide

Setmelanotide is a melanocortin-4 receptor (MC4R) agonist previously approved as IMCIVREE. This innovative treatment has shown effectiveness for patients with specific genetic disorders related to obesity, such as Bardet-Biedl syndrome and various deficiencies (POMC, PCSK1, or LEPR). The recent focus on acquired hypothalamic obesity showcases a crucial expansion of setmelanotide's indications, helping to meet the needs of a patient population with otherwise limited treatment options.

Clinical Trials Support Efficacy

The sNDA and Type II Variation submission are underpinned by compelling data from the Phase 3 TRANSCEND trial, which involved 120 patients with acquired hypothalamic obesity. The results from the study, discussed at the Endocrine Society's Annual Meeting, highlighted a remarkable -19.8% placebo-adjusted reduction in body mass index (BMI). This significant finding illustrates the effectiveness of setmelanotide, especially in patients who face unique challenges such as heightened hunger and reduced energy expenditure due to hypothalamic injury.

Patient Outcomes and Tolerability

Participants receiving setmelanotide therapy experienced notable reductions in BMI, with certain demographics showing higher efficacy. Adult patients registered an approximate -19.2% placebo-adjusted reduction in BMI at 52 weeks, while pediatric patients achieved an approximate -20.2% reduction. The overall safety profile from the TRANSCEND trial indicates that setmelanotide is generally well tolerated, with some patients experiencing common treatment-emergent adverse events such as nausea, vomiting, and injection site reactions.

Upcoming Investor Event

In the spirit of transparency and engagement with stakeholders, Rhythm will host a dedicated event titled "Commercial Readiness for Acquired Hypothalamic Obesity." Scheduled for September 24, 2025, this event aims to provide insights into market launch plans, regulatory progress, and the urgent patient need for effective treatment solutions. The event will feature perspectives from leading physicians who underscore the critical need for advancements in treatment for patients struggling with this condition.

Understanding Acquired Hypothalamic Obesity

This rare form of obesity arises from physical injury or structural abnormalities affecting the hypothalamus, disrupting the MC4R pathway. Patients typically face severe challenges such as increased hunger and reduced energy expenditure, leading them to gain weight rapidly after the onset of their condition. Understanding the nature of acquired hypothalamic obesity and its far-reaching impact on affected individuals is essential for developing effective therapies like setmelanotide.

Rhythm Pharmaceuticals' Commitment

Rhythm Pharmaceuticals is dedicated to advancing innovative treatments that positively influence the lives of patients and families dealing with rare neuroendocrine disorders. With setmelanotide, the company is taking a significant step toward providing effective solutions to those affected by significant obesity-related challenges—not only in the U.S. but also in European territories.

Contact for Further Information

For more details, the company encourages interested parties to connect with its Investor Relations team. Rhythm Pharmaceuticals is focused on ensuring that those with rare conditions receive the support needed through cutting-edge therapies.

Frequently Asked Questions

What is setmelanotide used for?

Setmelanotide is used to treat obesity caused by genetic disorders and is currently under review for acquired hypothalamic obesity.

What does FDA's Priority Review mean?

A Priority Review designation indicates that the FDA believes the treatment offers significant advancements in medical care and requires expedited review.

How many patients are impacted by acquired hypothalamic obesity?

It is estimated that there are around 5,000 to 10,000 individuals in the U.S. living with this condition.

When is Rhythm's event focused on acquired hypothalamic obesity?

The event will take place on September 24, 2025, in Boston.

How does Rhythm Pharmaceuticals contribute to patient care?

Rhythm is committed to developing therapies aimed at improving the quality of life for patients suffering from rare neuroendocrine diseases and obesity.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 100

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 154

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
191 Schools Honored for Academic Growth Success

Updated Category News Views 65

Celebrating Educational Progress Nationwide In a world where numbers fly off the stock tickers and translate into dollar signs in some corner office, it's refreshingly humbling to find real gains being celebrated in the educational sector. Curriculum Associates has tipped their hat to 191 schools that have done something remarkable: they've pushed students to stretch...

Continue Reading
ISC2 Launches AI Security Academy for Cyber Pros

Updated Category News Views 22

AI-Driven Threats Demand Expert Attention Every corner of the tech world has been blabbering about AI, but when it comes to cybersecurity, it's a whole different beast entirely. ISC2—a nonprofit that I like to think of as the cyber wizards’ guild—just threw a lifeline to cybersecurity folks who are swimming in the deep end of AI. With their shiny new AI Security...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 32

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Flexible Packaging Market to Hit $384.32B by 2031

Updated Category News Views 17

Packaging's Flexible Future Alright, here's the skinny: you might want to adjust those portfolios if you're watching the materials sector, because the flexible packaging market ain't just loosening up—it's stretching out like never before. By 2031, we're talking about it raking in a solid $384.32 billion, climbing from $313.25 billion in 2026. That's a not-so-shabby...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 87

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Jones Soda Expands into Nutrition with UCAN Deal

Updated Category News Views 145

Well, Jones Soda Co. (CSE: JSDA) is stirring the pot with its recent move to acquire the UCAN functional nutrition assets. Popped the news on November 12, 2026, and it turns out they've shelled out a cool $700,000 in cash and taken on $500,000 in liabilities for the privilege. This isn't some casual shuffle of dollars and cents—this one's a strategic gambit aimed at...

Continue Reading
Gwen Stefani Kicks Off OCVIBE's New Concert Hall

Updated Category News Views 101

A Homecoming Steeped in Nostalgia Orange County’s about to do a serious throwback, folks! Gwen Stefani is set to headline the opening concert at OCVIBE's spanking new concert hall in Anaheim on March 17, 2027. Curious choice for their opener? Hardly. This gal's practically woven into the county’s tapestry—her roots run deep here, enough to make even the casual music...

Continue Reading

Top 5 Most Recently Viewed Articles

Volta Finance Limited: Monthly Insights and Performance Metrics

Updated Category News Views 252

Understanding Volta Finance Limited's Performance for September 2025 Volta Finance Limited (VTA / VTAS) recently released its monthly report for September 2025. This report sheds light on the performance metrics that have shaped the company's strategies and outcomes over the past month, illustrating how they navigate an ever-changing financial landscape. Performance...

Continue Reading
Class Actions Alert: Understanding Investor Rights for SOC, LMT, NVO, LINE

Updated Category News Views 213

Understanding Class Action Lawsuits for Shareholders In today’s fast-paced investment world, shareholders must stay informed about class action lawsuits that may affect their investments. A recent alert highlights key class actions involving four publicly-traded companies, offering investors a glimpse into their rights and potential next steps. Sable Offshore Corp....

Continue Reading
Exploring ONCT-534: New Insights on Advanced Prostate Cancer

Updated Category News Views 202

Recent Updates on ONCT-534 for Advanced Prostate Cancer Oncternal Therapeutics, Inc. (NASDAQ: ONCT) has unveiled encouraging updates regarding its investigational therapy, ONCT-534, specifically targeting relapsed or refractory metastatic Castration-Resistant Prostate Cancer (mCRPC). This exciting development stems from the company’s ongoing Phase 1/2 Study, known as...

Continue Reading
GDS Holdings Celebrates Successful IPO of C-REIT in Shanghai

Updated Category News Views 197

GDS Holdings Completes C-REIT IPO on Shanghai Stock Exchange Shanghai, China — GDS Holdings Limited (NASDAQ: GDS; HKEX: 9698), a prominent developer and operator of high-performance data centers, has recently triumphantly finished its initial public offering (IPO) for the China REIT (C-REIT) on the Shanghai Stock Exchange. This achievement marks a significant milestone...

Continue Reading
Surge in Russian Stocks: MOEX Russia Index Reaches New Heights

Updated Category News Views 255

Russian Stocks Experience Notable Gains In recent trading sessions, Russian stocks showed significant upward movement, showcasing the resilience of various sectors within the economy. With the MOEX Russia Index closing higher, this is an indication of investor optimism and market recovery. Key Contributors to Market Gains Sector Performance Highlights The increase in the...

Continue Reading